A detailed history of Xtx Topco LTD transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 61,515 shares of LCTX stock, worth $56,593. This represents 0.01% of its overall portfolio holdings.

Number of Shares
61,515
Holding current value
$56,593
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$0.89 - $1.47 $54,748 - $90,427
61,515 New
61,515 $61,000
Q4 2023

Feb 13, 2024

BUY
$0.91 - $1.35 $24,603 - $36,499
27,037 New
27,037 $29,000
Q3 2022

Nov 14, 2022

BUY
$1.13 - $1.77 $55,658 - $87,181
49,255 Added 209.13%
72,807 $82,000
Q2 2022

Aug 15, 2022

BUY
$1.12 - $1.61 $26,378 - $37,918
23,552 New
23,552 $37,000
Q1 2022

May 13, 2022

SELL
$1.21 - $2.48 $16,249 - $33,303
-13,429 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$1.84 - $2.68 $24,709 - $35,989
13,429 New
13,429 $33,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $156M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Xtx Topco LTD Portfolio

Follow Xtx Topco LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.